Complex diseases affect us all. Illumina is committed to advancing our understanding of complex diseases and how they will be diagnosed and treated.
Complex diseases result from a combination of genetic and environmental factors, many of which are not understood. These diseases include neurodegenerative, psychiatric, and autoimmune disorders, and others.
The expanding Illumina complex disease product portfolio includes array and next-generation sequencing (NGS) technologies that are helping drive a revolution in complex disease genomics. These solutions deliver high-quality, reproducible results that accelerate research on various complex diseases. These discoveries have the potential to lead to life-changing improvements for patients and their loved ones.
This review gives a general overview of how genomic technologies and NGS can help in the study of complex diseases, and highlights recent publications featuring Illumina technology.Read Publication Review
Q&A with Chief Medical Officer Phil Febbo, MDRead Article
Sano Genetics protects individual genetic information ownership while connecting people to meaningful research.Read Interview
Partnership aims to accelerate NGS adoption for clinical infectious disease testingRead Article
There are many genetic loci involved in cancer risk. Read more about how using NGS to understand the polygenicity of cancer can help researchers predict cancer risk and customize precision prevention.Learn More